Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
Arthroscopy, Sports Medicine, and Rehabilitation
|
May 24, 2021
Prevalence of Prescription Opioids for Nonoperative Treatment of Rotator Cuff Disease Is High
Jacob Gorbaty, Susan M Odum, Meghan K Wally, et al.
Journal of Surgical Orthopaedic Advances
|
February 20, 2019
Opioid Prescribing in the Pediatric Orthopaedic Trauma Population
Robert T Simril, Brian P Scannell, Meghan K Wally, et al.
Journal of Opioid Management
|
October 25, 2023
Adherence to legislation limiting opioid prescription duration following musculoskeletal injury
Meghan K Wally, Michael E Thompson, Susan Odum, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1
Robert L Dow, Jian-Cheng Li, Michael P Pence, et al.
The Journal of Emergency Medicine
|
March 15, 2024
Opioid Prescribing Rate for Nonoperative Distal Radius Fractures and Clinician Response to a Clinical Decision Support Alert
Ben Averkamp, Katherine Li, Meghan K Wally, et al.
Journal of Opioid Management
|
January 8, 2024
Patients with glenohumeral arthritis are more likely to be prescribed opioids in the emergency department or urgent care setting
Jacob Gorbaty, Meghan K Wally, Susan Odum, et al.
The Journal of Foot and Ankle Surgery : Official Publication of the American College of Foot and Ankle Surgeons
|
November 27, 2021
Opioid Prescribing Risk Factors in Nonoperative Ankle Fractures: The Impact of a Prospective Clinical Decision Support Intervention
Andrew Wohler, David Macknet, Rachel B Seymour, et al.
Iscience
|
March 24, 2025
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies
Rachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
The Lancet. Infectious Diseases
|
February 27, 2025
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial
Ghady Haidar, Steven Thomas, Paul Loubet, et al.
JAMA Network Open
|
April 26, 2023
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials
Rachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
Arthroscopy, Sports Medicine, and Rehabilitation
|
May 24, 2021
Prevalence of Prescription Opioids for Nonoperative Treatment of Rotator Cuff Disease Is High
Jacob Gorbaty, Susan M Odum, Meghan K Wally, et al.
Journal of Surgical Orthopaedic Advances
|
February 20, 2019
Opioid Prescribing in the Pediatric Orthopaedic Trauma Population
Robert T Simril, Brian P Scannell, Meghan K Wally, et al.
Journal of Opioid Management
|
October 25, 2023
Adherence to legislation limiting opioid prescription duration following musculoskeletal injury
Meghan K Wally, Michael E Thompson, Susan Odum, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1
Robert L Dow, Jian-Cheng Li, Michael P Pence, et al.
The Journal of Emergency Medicine
|
March 15, 2024
Opioid Prescribing Rate for Nonoperative Distal Radius Fractures and Clinician Response to a Clinical Decision Support Alert
Ben Averkamp, Katherine Li, Meghan K Wally, et al.
Journal of Opioid Management
|
January 8, 2024
Patients with glenohumeral arthritis are more likely to be prescribed opioids in the emergency department or urgent care setting
Jacob Gorbaty, Meghan K Wally, Susan Odum, et al.
The Journal of Foot and Ankle Surgery : Official Publication of the American College of Foot and Ankle Surgeons
|
November 27, 2021
Opioid Prescribing Risk Factors in Nonoperative Ankle Fractures: The Impact of a Prospective Clinical Decision Support Intervention
Andrew Wohler, David Macknet, Rachel B Seymour, et al.
Iscience
|
March 24, 2025
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies
Rachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
The Lancet. Infectious Diseases
|
February 27, 2025
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial
Ghady Haidar, Steven Thomas, Paul Loubet, et al.
JAMA Network Open
|
April 26, 2023
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials
Rachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
Page
of 8